Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB105 in amyotrophic lateral sclerosis
NCT04494256Phase 2Terminated
- Sponsor
- Biogen
- Start
- Sep 2020
- Primary completion
- Aug 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
A Phase 2 trial of BIIB105 in amyotrophic lateral sclerosis (ALS), sponsored by Biogen. Started Sep 2020; status: terminated.
02
Drugs
BIIB105
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04494256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04494256.